Primary tricuspid regurgitation: a rare case report
DOI:
https://doi.org/10.18203/2349-3933.ijam20242323Keywords:
Tricuspid regurgitation, Infective endocarditis, Right heart failureAbstract
Tricuspid regurgitation is no longer a forgotten valve as TR can be clinical challenge for the treating physician especially patients with moderate to severe tricuspid regurgitation. The aetiology can be primary and secondary TR of which secondary TR is more common with female predominance. Another entity called isolated TR is now seen. Primary TR due to infective endocarditis is a rare condition. Clinical examination must look for signs of right heart failure. Investigations like Transthoracic and transesophageal echocardiogram has to meticulously done to grade the severity of TR and look for morphological changes. Medical management must be tailored made for patients based upon the severity and the clinicians must know when to refer to the valve team for appropriate intervention.
References
Badano L, Muraru D, Enriquez-Sarano M. Assessment of functional tricuspid regurgitation. Eur Heart J. 2013;34:1875-85.
Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897-902.
Wang N, Fulcher J, Abeysuriya N, McCrady M, Wilcox I, Celermajer D, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. 2019;40:476-84.
Hahn RT, Badano LP, Bartko PE, Muraru D, Maisano F, Zamorano JL, et al. Tricuspid regurgitation: recent advances in understanding pathophysiology, severity grading and outcome. Eur Heart J Cardiovasc Imaging. 2022;23:913-29.
tricuspid valve disease. Ann Cardiothorac Surg. 2017;6:204-13.
Paniagua D, Aldrich HR, Lieberman EH. Increased prevalence of significant tricuspid regurgitation in patients with transvenous pacemakers leads. Am J Cardiol. 1998;82:1130-2.
Dreyfus GD, Martin RP, Chan KM, Dulguerov F, Alexandrescu C. Functional tricuspid regurgitation: a need to revise our understanding. J Am Coll Cardiol. 2015;65:2331-6.
Wang TKM, Akyuz K, Mentias A, Kirincich J, Duran Crane A, Xu S, et al. Contemporary etiologies, outcomes, and novel risk score for isolated tricuspid regurgitation. JACC Cardiovasc Imaging. 2022;15:731-44.
Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, et al. European Association of Echocardiography. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307-32.
Sherif NA, Morra ME, Thanh LV, Elsayed GG, Elkady AH, Elshafay A, et al. Torsemide versus furosemide in treatment of heart failure: a systematic review and meta‐analysis of randomized controlled trials. J Eval Clin Pract. 2020;26:842-51.
Nishimura RA, Otto CM, Bonow RO. AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:57-185.
Vahanian A, Alfieri O, Andreotti F. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451–96.
McCarthy PM, Bhudia SK, Rajeswaran J. Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg, 2004;127:674-85.
